Neoadjuvant therapy for breast cancer has no benefits in routine clinical practice
Upcoming SlideShare
Loading in...5
×
 

Neoadjuvant therapy for breast cancer has no benefits in routine clinical practice

on

  • 362 views

 

Statistics

Views

Total Views
362
Views on SlideShare
362
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Neoadjuvant therapy for breast cancer has no benefits in routine clinical practice Neoadjuvant therapy for breast cancer has no benefits in routine clinical practice Document Transcript

    • Editoriale Page 1 of 1 Neoadjuvant therapy for breast cancer has no benefits in routine clinical practice Our study, with a median follow-up of 11 years, confirms that, for patients with primary operable non-metastatic breast cancer, neoadjuvant chemotherapy failed to improve overall survival. Then added value of neoadjuvant strategy for patients clinical benefit remains uncertain without demonstrating improvement regarding health related quality of life. Furthermore, we found no difference in the final mastectomy rate between the treatment groups. Of note, it is important to underline that these results are based on an historical cohort. Such bias is inherent to long-term endpoint studies. Never mind our results underline that clinicians should pay caution against the use of neoadjuvant chemotherapy in an unselected population. Then we suggest that the use of neoadjuvant therapy in clinical practice should be carefully discussed before implementation to take into accounts the benefits and risks for the patient. Quality of life could be the cornerstone of this discussion. Bibliographic Reference: Le Ray I et al.: "Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11years using propensity score matching", Eur J Cancer. 2012 Apr 16. [Epub ahead of print Franck Bonnetain Biostatistics and Epidemiology Unit, Centre Georges Francois Leclerc (CGFL), Dijon, Francefile://C:Documents and SettingsutenteDesktopEdit_Bonnetain.htm 01/06/2012